Analysis of hepatitis associated aplastic anemia in children

doi:10.3969/j.issn.1004-583X.2024.07.010

Abstract

Abstract:

Objective To analyze the clinical manifestation, etiology and treatment of hepatitis associated aplastic anemia (HAAA) in children. Methods Clinical data of two children with HAAA were retrospectively analyzed. Results The two children were all male, with an average age of 5 years and 11 months. Hepatitis A, B and C virus, treponema pallidum, acquired immunodeficiency syndrome (AIDS) virus, Epstein-Barr virus (EBV), TORCH (Toxoplasma gondii, Rubella virus, Cytomegalovirus, Herpes simplex virus I and II) and parvovirus B19 were all negative. Case 1 treated with cyclosporine prednisone immunosuppression was partially relieved. Case 2 underwent allogeneic hematopoietic stem cell transplantation (brother donor brother) was completely relieved. Conclusion HAAA in children often occurs in the recovery period of acute hepatitis, with undetermined etiology. The treatment is mainly immunosuppressive.

Key words: hepatitis, anemia, aplastic, children

CLC Number:

Wu Qiupin, Yan Shiwei, He Xiaoyin, Li Yun, LU Liju, Wu Yi. Analysis of hepatitis associated aplastic anemia in children[J]. Clinical Focus, 2024, 39(7): 640-643.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2024.07.010

https://huicui.hebmu.edu.cn/EN/Y2024/V39/I7/640

Figures/Tables 3

References 24

[1]	Bastola S, Kc O, Khanal S, et al. Hepatitis-associated aplastic anemia from workout supplement: Rare but potentially fatal entity[J]. SAGE Open Med Case Rep, 2020, 8: 2050313X20901937.
[2]	Rauff B, Idrees M, Shah SA, et al. Hepatitis associated aplastic anemia: A review[J] Virol J, 2011, 8: 87. doi: 10.1186/1743-422X-8-87 pmid: 21352606
[3]	Jeong DC, Chung NG, Kang HJ, et al. Epidemiology and clinical long-term outcome of childhood aplastic anemia in Korea for 15 years:Retrospectivestudy of the Korean Society of Pediatric Hematology Ontology(KSPHO)[J]. Pediatr Hematol Oncol,201 1, 33(3): 172-178.
[4]	Patel KR, Bertuch A, Sasa GS, et al. Features of hepatitis in hepatitis-associated aplastic anemia: Clinical and histopathologic study[J]. J Pediatr Gastroenterol Nutr, 2017, 64(1): e7-e12.
[5]	Wang H, Tu M, Fu R, et al. The clinical and immune characteristics of patients with hepatitis - associated aplastic anemia in China[J]. PLoS One, 2014, 9( 5): e98142.
[6]	乔晓红, 谢晓恬, 石苇, 等. 儿童肝炎相关再生障碍性贫血循证医学分析[J]. 中华实用儿科杂志, 2013, 28(15): 1155-1158.
[7]	Shah SA, La LA, Idrees M, et al. Hepatitis E virus-associated aplastic anaemia: The first case of its kind[J]. J ClinVirol, 2012, 54(1): 96-97.
[8]	Brown KE, Tisdale J, Barrett AJ, et al. Hepatitis-associated aplastic anemia[J]. N Engl J Med, 1997, 336(15):1059-1064.
[9]	尤亚红, 孟宪彬, 李星鑫, 等. 肝炎相关再生障碍性贫血患者长期随访研究[J]. 中国实验血液学杂志, 2017, 25(4):1130-1135.
[10]	穆静, 陈芳, 何强. 儿童肝炎相关再生障碍性贫血1例报告[J]. 临床肝胆病杂志, 2019, 35(8):1797-1799.
[11]	张晓妹, 罗荣牡. 儿童肝炎相关再生障碍性贫血的诊治进展[J]. 传染病信息, 2019, 32(2):171-174.
[12]	王丽佳, 江宇泳, 王鹏, 等. 戊型病毒性肝炎相关性再生障碍性贫血3例及文献复习[J]. 胃肠病学和肝病学杂志, 2013, 22(10):1046-1050.
[13]	Mori T, Onishi Y, Ozawa Y, et al. Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with hepatitis-associated aplastic anemia[J]. Int J Hematol, 2019, 109(6): 711-717. doi: 10.1007/s12185-019-02644-8 pmid: 30963471
[14]	Zhang X, Yang W, Yang D, et al. Comparison of hematopoieticstem celltrans plantation and immunosuppressive therapyas the first-linetreatmentoption for patient swith severehe patitis associatedaplasticanemia[J]. Front Immunol, 2023, 14:1146997.
[15]	Gafar F, Arifin H, Jurnalis YD, et al. Antituberculosis druginduced liver injury in children: Incidenceand risk factors during the two-month intensive phase of therapy[J]. Pediatr Infect Dis J, 2019, 38(1):50-53.
[16]	Chen Y, Lin N, Sun M. Clinical research of childhood hepatitis-associated aplastic anemia[J]. Chin Pediatr Emerg Med, 2015, 22(9): 603-606.
[17]	Wang H, Tu M, Fu R, et al. The clinical and immune characteristics of patients with hepatitis associated aplastic anemia in China[J]. PLoS One, 2014, 9(5): e98142.
[18]	Babushok DV, Grignon AL, Li Y, et al. Disrupted lymphocyte homeostasis in hepatitis associated acquired aplastic anemia is associated with short telomeres[J]. Am J Hematol, 2016, 91(2): 243-247. doi: 10.1002/ajh.24256 pmid: 26615915
[19]	Alsakkal M, AL Khateeb M, Alhalaby M, et al. Hepatitis associated aplastic anemia: A report of 3 cases associated with HAV[J]. J Pediatr Hematol Oncol, 2019, 41(3): e164-e166.
[20]	郭欢绪, 范丹, 张静宜, 等. 一线免疫抑制及造血干细胞移植治疗肝炎相关性再生障碍性贫血的疗效比较[J]. 临床血液学杂志 2024, 37(5):343-348.
[21]	Jalaeikhoo H, Khajeh-Mehrizi A. Immunosuppressive therapy in patients with aplastic anemia: A single-center retrospective study[J]. PLoS One, 2015, 10(5):e0126925.
[22]	Gonzalez-Casas R, Garcia-Buey L, Jones EA, et al. Systematic review: hepatitis-associated aplastic anaemia-a syndromeassociated with abnormal immunological function[J]. Aliment Pharmacol Ther, 2009, 30(5):436-443.
[23]	Mori T, Onishi Y, Ozawa Y, et al. Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with hepatitis-associated aplastic anemia[J]. Int J Hematol, 2019, 109(6):711-717. doi: 10.1007/s12185-019-02644-8 pmid: 30963471
[24]	戚永磊, 许多荣, 王顺清, 等. 不同的造血干细胞移植方式对重型再生障碍性贫血治疗效果的影响[J]. 新医学, 2012, 43(4):219-222.

病例	病程	DBil(μmol/L)	ALT(U/L)	AST(U/L)	TBA(μmol/L)	GGT(U/L)
1	入院时	231.7	3475	2275	346.7	94
	确诊时	3.73	119	75	6.7	41
2	入院时	131.02	2243	2262	294.1	150
	确诊时	8.21	280	105	60.6	50

病例	病程	DBil(μmol/L)	ALT(U/L)	AST(U/L)	TBA(μmol/L)	GGT(U/L)
1	入院时	231.7	3475	2275	346.7	94
	确诊时	3.73	119	75	6.7	41
2	入院时	131.02	2243	2262	294.1	150
	确诊时	8.21	280	105	60.6	50

病例	病程	WBC(×10⁹/L)	Neu(×10⁹/L)	RBC(×10¹²/L)	HGB(g/L)	PLT(×10⁹/L)	骨髓增生程度	分型
1	入院时	0.5	0.23	3.5	97	248
	确诊时	1.8	0.23	3.4	98	55	15%	重型
2	入院时	4.7	3.56	4.2	118	154
	确诊时	3.0	0.68	3.8	120	18	10%	重型

病例	病程	WBC(×10⁹/L)	Neu(×10⁹/L)	RBC(×10¹²/L)	HGB(g/L)	PLT(×10⁹/L)	骨髓增生程度	分型
1	入院时	0.5	0.23	3.5	97	248
	确诊时	1.8	0.23	3.4	98	55	15%	重型
2	入院时	4.7	3.56	4.2	118	154
	确诊时	3.0	0.68	3.8	120	18	10%	重型

病例	CD3+ (65%~79%)	CD3+CD4+ (34%~52%)	CD3+CD8+ (21%~39%)	CD4/CD8 (0.53%~2.31%)	CD3-CD19+ (9.02%~14.1%)	CD56+CD16+ (10%~19.78%)
1	80.69	10.97	60.56	0.18	18.53	2.57
2	88.95	56.21	26.06	2.16	7.16	2.56